These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26614)

  • 41. Effect of host-versus-graft and graft-versus-host reactions on the immune response of mice to sheep red blood cells.
    Zaleski M
    Folia Biol (Praha); 1971; 17(2):111-22. PubMed ID: 4396932
    [No Abstract]   [Full Text] [Related]  

  • 42. [Preferential efficicacy of immunocomplexes in the facilitation of tumor allografts].
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1973 Nov; 124(4):567-72. PubMed ID: 4134880
    [No Abstract]   [Full Text] [Related]  

  • 43. Suppression of GVH reaction in F1 hybrid mice by foetal liver cells.
    Siegl E; Brock J; Schulze HA
    Folia Biol (Praha); 1982; 28(6):409-14. PubMed ID: 6761153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The influence of the age of donors and recipients on the regional graft-versus-host reaction in mice.
    Skowron-Cendrzak A; Kubera M; Bubak-Satora M; Godowicz W
    Arch Immunol Ther Exp (Warsz); 1991; 39(3):185-91. PubMed ID: 1810211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of tumour homografts by the local graft-versus-host reaction.
    Medzihradský J; Klobusická M; Koníková E; Novotná L
    Neoplasma; 1971; 18(2):133-40. PubMed ID: 4397019
    [No Abstract]   [Full Text] [Related]  

  • 46. Transfer of tumor-specific immunity with RNA: inhibition of growth of murine tumor isografts.
    Ramming KP; Pilch YH
    J Natl Cancer Inst; 1971 Apr; 46(4):735-50. PubMed ID: 4102341
    [No Abstract]   [Full Text] [Related]  

  • 47. [Use of heterologous antireceptor antibodies for specific reversal of acute homologous disease in mice].
    Nesterenko VG; Gruner Sh; Rubakova EI; Babadzhanov AS
    Biull Eksp Biol Med; 1980 Nov; 90(11):588-90. PubMed ID: 7192584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antilymphocytic antibodies and marrow transplantation. V. Suppression of secondary disease by host-versus-theta-graft reaction.
    Thierfelder S; Rodt H
    Transplantation; 1977 Jan; 23(1):87-92. PubMed ID: 319574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune status of mice tolerant of living cells. II. Continuous presence and nature of facilitation-enhancing antibodies in tolerant animals.
    Voisin GA; Kinsky RG; Duc HT
    J Exp Med; 1972 May; 135(5):1185-203. PubMed ID: 4623319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Passive allograft enhancement by subclasses of polyclonal antibodies directed toward restricted regions of the major histocompatibility complex.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1982 May; 33(5):492-9. PubMed ID: 6806954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of placental extracts on the immune response to histocompatibility antigens: class deviation of alloantibody response and allograft enhancement.
    Gupta GS; Kinsky RG; Duc HT; Voisin GA
    Am J Reprod Immunol (1980); 1984; 6(3):117-23. PubMed ID: 6517178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolution of alloantibodies and suppressor cells in allografted mice treated for passive enhancement.
    Duc HT; Kinsky RG; Monnot P; Voisin GA
    Cell Immunol; 1985 Oct; 95(1):180-94. PubMed ID: 4028170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune status of mice tolerant of living cells. III. Presence and evolution of cells cytotoxic to the tolerated strain.
    Oppenheim ES; Kinsky R; Voisin GA
    Transplantation; 1977 Oct; 24(4):274-81. PubMed ID: 919023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attempts to demonstrate an in vivo role for serum blocking factors in tolerant mice.
    Brent L; Brooks C; Lubling N; Thomas AV
    Transplantation; 1972 Sep; 14(3):382-7. PubMed ID: 4404695
    [No Abstract]   [Full Text] [Related]  

  • 55. Differential development of murine immunocompetence to transplantation antigens.
    Fidler JM
    Transplantation; 1972 Dec; 14(6):716-21. PubMed ID: 4404986
    [No Abstract]   [Full Text] [Related]  

  • 56. Splenic foci of cytotoxic lymphocytes in a graft-versus-host reaction.
    Skinner MA; Marbrook J; Baguley BC
    Int Arch Allergy Appl Immunol; 1978; 56(4):334-43. PubMed ID: 24592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of IgG1 in immunological enhancement--facilitation.
    Kinsky RG; Voisin GA; Duc HT
    Adv Exp Med Biol; 1973; 29(0):435-42. PubMed ID: 4605076
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunologic enhancement of allogeneic tumor growth with soluble histocompatibility-2 antigens.
    Law LW; Appella E; Wright PW; Strober S
    Proc Natl Acad Sci U S A; 1971 Dec; 68(12):3078-82. PubMed ID: 4108871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ia versus K/D antigens in immunological enhancement of tumor allografts.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1978 Apr; 25(4):182-7. PubMed ID: 635985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maternal immunization to paternal antigens in multiparous mice.
    Baines MG; Ansell J; McLaren A; Micklem HS
    J Reprod Fertil; 1975 Feb; 42(2):293-9. PubMed ID: 235026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.